Cited by 225Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTryptophan and brain disorders

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Open access

Alvarez, Enric, Perez, Victor, Dragheim, Marianne, Loft, Henrik, Artigas, Francesc·2012·The International Journal of Neuropsychopharmacology

DOI 10.1017/s1461145711001027PMC PMC3349292

Open this paper in CoChat — free account Open PDF

Abstract

The efficacy, safety, and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in patients with DSM-IV-TR major depressive disorder (MDD) were evaluated. Lu AA21004 is a novel antidepressant that is a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1A receptor agonist, 5-HT1B receptor partial agonist and inhibitor of the 5-HT transporter in recombinant cell lines. In this 6-wk, multi-site study, 429 patients were randomly assigned (1:1:1:1) to 5 or 10 mg Lu AA21004, placebo or 225 mg venlafaxine XR. All patients had a baseline Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥ 30. The primary efficacy analysis was based on the MADRS total score adjusting for multiplicity using a hierarchical testing procedure starting with the highest dose vs. placebo. Lu AA21004 was statistically significantly superior to placebo (n=105) in mean change from baseline in MADRS total score at week 6 (p<0.0001, last observation carried forward), with a mean treatment difference vs. placebo of 5.9 (5 mg, n=108), and 5.7 (10 mg, n=100) points. Venlafaxine XR (n=112) was also significantly superior to placebo at week 6 (p<0.0001). In total, 30 patients withdrew due to adverse events (AEs)--placebo: four (4%); 5 mg Lu AA21004: three (3%); 10 mg Lu AA21004: seven (7%); and venlafaxine: 16 (14%). The most common AEs were nausea, headache, hyperhidrosis, and dry mouth. No clinically relevant changes over time were seen in the clinical laboratory results, vital signs, weight, or ECG parameters. In this study, treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with MDD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1017/s1461145711001027

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Flow chart of patient disposition. AE, Adverse events, ITT, intention to treat; LoE, lack of efficacy; MADRS, Montgomery–Åsberg Depression Rating Scale; PBO, placebo; Ven 225, venlafaxine XR 225 mg.CC BY-NC-SA · PubMed Central

Fig. 2 Mean change from baseline in Montgomery–Åsberg Depression Rating Scale (MADRS) total scores (ANCOVA, FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last observation carried forward; OC, observed cases.CC BY-NC-SA · PubMed Central

Fig. 3 Mean change from baseline in Hamilton Rating Scale for Anxiety (HAMA) total scores (ANCOVA, FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last observation carried forward; OC, observed cases. Some patients were excluded due to the use of a non-validated scale in France.CC BY-NC-SA · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Untitled work
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,703
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Untitled work
(1998) · PubMed · Cited by 10,216
Untitled work
(1976) · Medical Entomology and Zoology · Cited by 8,899
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892

Show all 31 references

Sorted by citations

Items 101–200 of 225

New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine
Orsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Vellante, F., Fornaro, M., Fiengo, A. L. C., Mazza, M., Vecchiotti, R., et al. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1173545 · Cited by 26
YY1 (Yin‐Yang 1), a transcription factor regulating systemic inflammation, is involved in cognitive impairment of depression
Lü, J., Jin, K., Jiao, J., Liu, R., Mou, T., Chen, B., Zhang, Z., Jiang, C., Zhao, H., Wang, Z., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13510 · Cited by 25
Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA)
Ngen, C. C., Zain, A. M., Hemrungrojn, S., Ung, E. K., Kwansanit, P., Yong, K. C. A., Chong, M. S. W., Inpa, C., Yen, T. H., Yeoh, B. B. D., et al. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1477746 · Cited by 24
The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis
Fu, J., & Chen, Y. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3633-z · Cited by 24
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
McIntyre, R. S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150589 · Cited by 23
Meta-analysis: Second generation antidepressants and headache
Telang, S., Walton, C., Olten, B., & Bloch, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.047 · Cited by 23
The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis
Kamp, C. B., Petersen, J. J., Faltermeier, P., Juul, S., Siddiqui, F., Moncrieff, J., Horowitz, M. A., Hengartner, M. P., Kirsch, I., Gluud, C. N., et al. (2024) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796024000520 · Cited by 23
A quantitative LC-MS/MS method for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma, and its application to a toxicokinetic study
Qin, M., Qiao, H., Yuan, Y., & Shao, Q. (2018) · Analytical Methods · doi:10.1039/c7ay02642k · Cited by 21
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 23
Vortioxetine for the treatment of major depressive disorder
Tritschler, L., Felice, D., Colle, R., Guilloux, J., Corruble, E., Gardier, A. M., & David, D. J. P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.950655 · Cited by 23
Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed Rats
Hatherall, L. C., Sánchez, C., & Morilak, D. A. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw105 · Cited by 21
The well of novel antidepressants: running dry
Blier, P. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100098 · Cited by 20
Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males
Nissen, T. D., Laursen, B., Viardot, G., L’Hostis, P., Danjou, P., Sluth, L. B., Gram, M., Bastlund, J. F., Christensen, S. R., & Drewes, A. M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.039 · Cited by 16
Effects of 5-HT7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia
Maxwell, J. K., Gleason, S. D., Falcone, J. F., Svensson, K. A., Balcer, O. M., Li, X., & Witkin, J. M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.11.019 · Cited by 19
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies
Mattingly, G. W., Necking, O., Schmidt, S. N., Reines, E. H., & Ren, H. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2178082 · Cited by 20
Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms
Xue, L., Bocharova, M., Young, A. H., & Aarsland, D. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.003 · Cited by 18
Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials
Li, G., Wang, X., & Ma, D. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0396-9 · Cited by 19
A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA)
Yang, Y. K., Chen, C., Tsai, C.-F., Chang, C., Lai, T.-J., Lee, C.-T., Lin, C., Lan, T., & Herr, K. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1980869 · Cited by 18
Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study
Thase, M. E., Jacobsen, P. L., Hanson, E., Xu, R., Tolkoff, M., & Murthy, N. V. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.002 · Cited by 18
Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis
Nußbaumer-Streit, B., Morgan, L. C., Reichenpfader, U., Greenblatt, A. M., Hansen, R. A., Noord, M. V., Lux, L. J., Gaynes, B. N., & Gartlehner, G. (2014) · CNS Drugs · doi:10.1007/s40263-014-0169-z · Cited by 17
Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain
Fernández‐Pastor, B., Ortega, J. E., & Meana, J. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3112-y · Cited by 19
Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults
Matsuno, K., Nakamura, K., Aritomi, Y., & Nishimura, A. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.381 · Cited by 16
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder
Vieta, E., Florea, I., Schmidt, S. N., Areberg, J., & Ettrup, A. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000271 · Cited by 16
Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials
Mahableshwarkar, A. R., Affinito, J., Reines, E. H., Xu, J., Nomikos, G. G., & Jacobsen, P. L. (2019) · CNS Spectrums · doi:10.1017/s109285291900097x · Cited by 16
Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism
Smagin, G. N., Song, D., Budac, D. P., Waller, J. A., Li, Y., Pehrson, A. L., & Sánchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.001 · Cited by 16
Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats
Riga, M. S., Sánchez, C., Celada, P., & Artigas, F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108238 · Cited by 14
Self-citation
Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder
Dubovsky, S. L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.904286 · Cited by 14
Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study
Carlo, V. D., Vismara, M. E. M., Grancini, B. M., Benatti, B., Bosi, M. F., Colombo, A., Viganò, C. A., & Dell’Osso, B. M. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2750 · Cited by 14
A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder
Naik, H., Chan, S., Vakilynejad, M., Chen, G., Loft, H., Mahableshwarkar, A. R., & Areberg, J. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12513 · Cited by 13
Self-citation
Asenapine in the Treatment of Bipolar Depression
El‐Mallakh, R. S., Nuss, S., Gao, D. F., Gao, Y., Ahmad, S., Schrodt, C., & Adler, C. M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4597 · Cited by 13
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
Rancāns, E., Zámbori, J., Dalsgaard, M. K., Baayen, C., Areberg, J., Ettrup, A., & Florea, I. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000326 · Cited by 13
Depression and Cerebrovascular Disease: Could Vortioxetine Represent a Valid Treatment Option?
Carta, M. G., Pala, A. N., Finco, G., Musu, M., & Moro, M. F. (2015) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901511010144 · Cited by 12
Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test
Refsgaard, L. K., Haubro, K., Pickering, D. S., Stuart, S. A., Robinson, E. S. J., & Andreasen, J. T. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4407-6 · Cited by 13
Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis
He, H., Wang, W., Lyu, J., Zheng, J., Guo, L., An, X., Fan, Y., & Ma, X. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.10.018 · Cited by 12
Vortioxetine overdose in a suicidal attempt
Mazza, M. G., Rossetti, A., Botti, R. E., & Clerici, M. (2018) · Medicine · doi:10.1097/md.0000000000010788 · Cited by 12
The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study
Zhang, Y., Lai, S., Zhang, J., Wang, Y., Zhao, H., He, J., Huang, D., Chen, G., Qi, Z., Chen, P., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.272 · Cited by 11
Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials
Yang, X. S., Fang, S., Lyu, W., Hu, Y., Xu, H., Jiang, X., Zhao, Y., Zhang, Y., Li, J., & Kuang, W. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13709 · Cited by 12
Decreased neutrophil-to-lymphocyte ratio predicted cognitive improvement in late-life depression treated with vortioxetine: Findings from an eight-week randomized controlled trial
Xue, L., Lewis, E. T., Bocharova, M., Young, A. H., & Aarsland, D. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.01.029 · Cited by 12
The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
Zheng, J., Wang, Z., & Li, E. (2019) · African Health Sciences · doi:10.4314/ahs.v19i1.48 · Cited by 11
Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications
Zimmerman, M., Balling, C., Chelminski, I., & Dalrymple, K. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.012 · Cited by 10
Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine
Lachaîne, J., Beauchemin, C., Bibeau, J., Patenaude, J., Chokka, P. R., Proulx, J., & Bougie, J. K. (2019) · CNS Spectrums · doi:10.1017/s1092852919000853 · Cited by 11
Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine
Chen, G., Nomikos, G. G., Affinito, J., Jacobson, W., Zhao, Z., Wang, S., & Xie, J. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.577 · Cited by 10
Do Hamilton depression scale items have the capacity to differentiate melancholic and non-melancholic depressive sub-types?
Parker, G. B., & Hadži-Pavlović, D. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.138 · Cited by 10
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
Baldwin, D. S., & Nutt, D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.018 · Cited by 11
Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
Manna, C. K., Ranjan, R., Kumar, P., Ahmad, S., & Nath, S. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_160_23 · Cited by 9
Vortioxetine in the treatment of major depressive disorder
Baldwin, D. S., & Hanumanthaiah, V. B. (2015) · Future Neurology · doi:10.2217/fnl.14.69 · Cited by 9
Emerging drugs for major depressive disorder: an update
Rizvi, S. J., & Kennedy, S. H. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.681301 · Cited by 9
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
Chokka, P. R., Ge, H., Bougie, J. K., Ettrup, A., & Clerzius, G. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211013148 · Cited by 8
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study
Nicola, M. D., Adair, M., Rieckmann, A., & Cronquist Christensen, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241260996 · Cited by 8
Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
Montano, C. B., Jackson, W. C., Vanacore, D., & Weisler, R. H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s337703 · Cited by 8
Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity
Zimmerman, M., Multach, M. D., Walsh, E. K., Rosenstein, L. K., Gazarian, D., & Clark, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0314-y · Cited by 7
A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
Bose, R., Hamdani, S. U., Minhas, F. A., & Herr, K. J. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2031146 · Cited by 7
Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling
Zimmerman, M., Clark, H., Multach, M. D., Walsh, E. K., Rosenstein, L. K., & Gazarian, D. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.041 · Cited by 6
Relative short‐term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder
Kennedy, S. H., Grouin, J., Cadour, S., Robert, V., & Picarel-Blanchot, F. (2018) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2646 · Cited by 6
HTR1D regulates the PI3K/Akt signaling pathway to impact glioblastoma development and resistance to temozolomide
Zhang, H., Liu, Z., Cheng, J., Jiang, Y., Zhang, C., Zhang, C., & Li, Y.-L. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111748 · Cited by 5
Meta-analysis of placebo group dropout in adult antidepressant trials
Li, F., Nasir, M., Olten, B., & Bloch, M. H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109777 · Cited by 5
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
Ma, D., Li, G., & Wang, X. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s103173 · Cited by 6
The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine
François, C., Nielsen, R. Z., Danchenko, N., Williams, V. S. L., & Lançon, C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1299701 · Cited by 5
Systematic review of gender bias in vortioxetine clinical trials
Santos-Casado, M., Guisado-Gil, A. B., & Santos‐Ramos, B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110088 · Cited by 5
DEPRESSION AND COGNITIVE DISTURBANCES: EXPERIENCE OF VORTIOXETINE USE IN NEUROLOGIC PRACTICE
Azimova, Y. É. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-11-36-39 · Cited by 4
Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials
Gao, S., Xie, X., Fan, L., & Zhang, D. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12214 · Cited by 5
The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature
Weiss, F., Pacciardi, B., D’Alessandro, G., Caruso, V., Maremmani, I., Pini, S., & Perugi, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020531 · Cited by 4
La vortioxétine : un nouvel antidépresseur pour traiter les épisodes dépressifs caractérisés
Colle, R., & Corruble, E. (2015) · L Encéphale · doi:10.1016/j.encep.2015.07.007 · Cited by 6
Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder
Liu, M. T. (2015) · World Journal of Pharmacology · doi:10.5497/wjp.v4.i1.17 · Cited by 4
Future Strategies for the Treatment of Depression
Grosso, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-14021-6_12 · Cited by 4
Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries
Tegin, C., Tegin, G., & El‐Mallakh, R. S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4559 · Cited by 4
Conditional power of antidepressant network meta-analysis
Holper, L. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03094-5 · Cited by 4
Antidepressant Signal Detection in the Clinical Trials Vortex
Dunlop, B. W., & Rapaport, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15com09934 · Cited by 4
Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Behzadifar, M., Dehghan, H., Saki, K., Behzadifar, M., Keshavarzi, A., Saran, M., & Sari, A. A. (2015) · Pharmacology & Pharmacy · doi:10.4236/pp.2015.64024 · Cited by 4
The efficacy of vortioxetine for the treatment of major depressive disorder
Dhir, A., & Sarvaiya, J. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.987131 · Cited by 4
A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality
Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., et al. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s491768 · Cited by 3
Vortioxetine versus reuptake inhibitors in adults with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
Barbosa, E. C., da Silva, G. H. S., Sbardelotto, Â. E. E., Barroso, D. C., de Lima, F. R., Paez, L. E. F. E., Lança, S. B., Petrucci, A. B. C., Guimarães, F. B. D. M., & Nascimento, A. L. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104222 · Cited by 3
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 4
Effectiveness and Tolerability of Vortioxetine Oral Drops Versus Oral Tablets in Major Depressive Disorder: An Analysis of a Real-World Cohort Study in Switzerland
Hochstrasser, B., Hasler, G., Baumann, A., Bose, R., Reines, E. H., Kammerer, M. H., & Sousek, A. (2025) · CNS Drugs · doi:10.1007/s40263-025-01207-2 · Cited by 3
Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition
Dawson, G. R. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5016 · Cited by 4
Vortioxetine (Brintellix®) and Levomilnacipran (Fetzima®): The Two Newest Additions to the Antidepressant Formulary
Roman, M. W., & Wilkinson, S. M. (2014) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.955155 · Cited by 3
The usefulness of psychometric tests in dental treatment of patients aged above 65
Koczorowski, R., Ewa, J.-B., & Gałczyńska‐Rusin, M. (2013) · Acta Odontologica Scandinavica · doi:10.3109/00016357.2013.817604 · Cited by 3
Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
Inoue, T., Fujimoto, S., Marumoto, T., Kitagawa, T., Ishida, K., Nakajima, T., Moriguchi, Y., Fujikawa, K., & Watanabe, K. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s335028 · Cited by 3
Donepezil and α‐synuclein Constipation: A 60 Month Follow-Up
Lepkowsky, C. M. (2022) · POJ Clinical Case Reports · doi:10.32648/2639-3298/4/1/1 · Cited by 2
Review of a New Multimodal Antidepressant Vortioxetine
Oppa, M., Cesnekova, D., Nosalova, G., & Ondrejka, I. (2016) · Acta Medica Martiniana · doi:10.1515/acm-2016-0011 · Cited by 3
Vortioxetine: a comprehensive update on a new-generation antidepressant
Evren, C. (2021) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2021.00115 · Cited by 2
A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
Ng, C. G., Abousheishaa, A. A., Low, S.-Y., Zainal, N. Z., Thong, K. S., Awaluddin, A., Loo, T. H., Yacob, S., Jaafar, N. R. N., Taib, N. I. A., et al. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.8.2583 · Cited by 1
A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression
Sankar, K., Viswanathan, S., Mugundan, U. M., Nazar, R. K., Ramasamy, S., & Rajanandh, M. G. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100129 · Cited by 2
Donepezil and α-synuclein Constipation: A 36 Month Follow-Up
Lepkowsky, C. M. (2019) · POJ Clinical Case Reports · doi:10.32648/2639-3298/2/1/002 · Cited by 2
Case Study 2
Bundgaard, C., Pehrson, A. L., Sánchez, C., & Bang‐Andersen, B. (2015) · Wiley eBooks · doi:10.1002/9781118788523.ch23 · Cited by 2
Antidepressant medications: a comprehensive review of efficacy, safety, and future directions
Shah, N., Parmar, J., Shandilya, S., Parmar, D., & Singhal, P. K. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253726 · Cited by 2
Developments in Psychopharmacology for Major Depressive Disorder
Chang, T. E., & Stahl, S. M. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.452 · Cited by 1
Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis
Behzadifar, M., Keshavarzi, A., Tofighian, A., Rastian, M., Zobidi, M., & Sari, A. A. (2015) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2015.510041 · Cited by 1
Vortioxetine – an antidepressant with a multifunctional mechanism of action
Wysokiński, A., & Sobów, T. (2016) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2016.0014 · Cited by 1
Vortioxetine for depression treatment in hospital setting: experience from a single psychiatric hospital
Васильевич, Л. О., Bugorskij, A. V., Михайловна, Г. Е., Ivanova, T. V., Kulikova, J. S., Lozinskaja, O. I., Sineva, A. I., Otmahova, U. A., & Otmahova, A. P. (2020) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2020-3-83-82 · Cited by 1
What role for ▼vortioxetine?
(2016) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2016.3.0387 · Cited by 1
Vortioxetine in major depressive disorder: a guide to its use in the EU
Garnock-Jones, K. P., & Lyseng-Williamson, K. A. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0217-x · Cited by 1
Donepezil and α-synuclein Constipation: A 48 Month Follow-Up
Lepkowsky, C. M. (2021) · POJ Clinical Case Reports · doi:10.32648/2639-3298/3/1/001 · Cited by 1
Comment on Fu, J. and Chen, Y.: The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis
Humes, E. D. C., & Brunoni, A. R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4531-y · Cited by 1
Electrophysiological Investigations on the Role of Selected Serotonin Receptors and the Serotonin Transporter on Serotonin Transmission in the Rat Brain
Lecours, M. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-3484
Future perspectives on the pharmacological management of depression
Yates, S., Smith, E., Alhaj, H. A., & McAllister-Williams, H. (2013) · Clinical Investigation · doi:10.4155/cli.12.152
Individualized Pharmacological Treatment of Depressive Disorders State of the Art and Recent Developments
Zirngibl, C. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000154
Antidepressivum mit unterschiedlichen Zielstrukturen und Wirkmechanismen
Volz, H. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0928-9
Vortioxetin — ein neues Antidepressivum?
Cseh, S., Köppl, A., Stegmann, B., & Haen, E. (2016) · NeuroTransmitter · doi:10.1007/s15016-016-5486-7

Authors: Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F.
Affiliations: Lundbeck (Denmark) (DK)
Consejo Superior de Investigaciones Científicas (ES)
Corresponding author: Dragheim, Marianne
ORCID: Artigas, Francesc
Venue: The International Journal of Neuropsychopharmacology
Publisher: Oxford University Press (OUP)
Published: 2011-07-18
Volume: 15
Issue: 05
Pages: 589-600
ISSN: 1461-1457 (ISSN-L)
1469-5111
DOI: 10.1017/s1461145711001027
PMC: PMC3349292
OpenAlex: W2048026164
Cited by: 225
References: 31
Citations by year: 2026: 4 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 13 · 2021: 11 · 2020: 9 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 20 · 2015: 33 · 2014: 27 · 2013: 19 · 2012: 11
FWCI: 13.82
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
Locations: The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Pfizer
AstraZeneca
Sanofi
Servier
H. Lundbeck A/S
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: vortioxetine, major depressive disorder, antidepressant efficacy, 5-HT3 receptor antagonists, 5-HT7 receptor antagonists, 5-HT1A receptor agonist, adverse events, drug tolerability
MeSH terms: Venlafaxine Hydrochloride, Vortioxetine, Adult, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Piperazines, Placebos, Psychiatric Status Rating Scales, Sulfides, Treatment Outcome, Antidepressive Agents, Second-Generation, Diagnostic and Statistical Manual of Mental Disorders, Receptor, Serotonin, 5-HT1A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks